Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective

Area of Science:

• Medical Oncology
• Surgical Oncology
• Clinical Research

Background:

• Advanced soft tissue sarcoma (aSTS) management lacks first-line therapy advances, yet overall survival (OS) has improved to a median of 20 months.
• Multiple second-line and beyond systemic therapy options exist, with increasing tailoring to histology and molecular subtypes.

Purpose of the Study:

• To characterize current patterns of care for advanced soft tissue sarcoma (aSTS) patients in Australia.
• To analyze the impact of patient and tumor characteristics on OS in a Victorian cohort.
• To evaluate the effectiveness of palliative-intent treatments in aSTS management.

Main Methods:

• Retrospective analysis of 671 advanced soft tissue sarcoma (aSTS) cases from 7 Australian sarcoma services (2010-2015).
• Descriptive analysis of clinicopathological factors and initial treatment patterns.
• Exploratory analysis of palliative-intent treatment modalities (surgery, radiotherapy, systemic therapy) and their impact on OS in the Victorian cohort (N=361).

Main Results:

• Approximately 80% of patients received palliative-intent treatment, including debulking surgery/metastasectomy (40%) and radiotherapy (71.7%).
• Palliative-intent systemic therapy was given to 51.5% of patients, with anthracycline-based regimens being most common.
• Median OS in the Victorian cohort was 15.4 months; palliative treatment conferred survival benefit, while UPS histology was associated with poorer OS.

Conclusions:

• Advanced soft tissue sarcoma (aSTS) in Australia is managed with diverse therapeutic modalities.
• Palliative-intent treatments demonstrate a survival benefit in advanced soft tissue sarcoma (aSTS).
• Future research will focus on healthcare resource utilization and cost estimation for this patient cohort.